Elutia Faces Nasdaq Delisting, Secures $15M Loan, and Divests SimpliDerm
ELUT sits 88% above its 52-week low of $0.5.
Summary
Elutia faces Nasdaq delisting, secures a $15M loan with warrants, and divests SimpliDerm for up to $11M amid continued losses.
Key Events · Legal and Risk Events · ELUT
-
Nasdaq Delisting Notice
Received August 6, 2026, for stock price below $1.00 for 30 consecutive days. Compliance deadline is February 2, 2027.
-
$15M Loan Secured
Senior secured term loan from Avenue Capital Group: $10M funded, $5M delayed draw. Includes warrants for 1,395,348 shares at $0.86.
-
SimpliDerm Divestiture
Agreement to sell SimpliDerm business for up to $11M: $8M base, $2M milestone, $1M earn-out.
-
Q2 Financials
Net loss of $7.6M, cash of $19.9M. Company states funding sufficient through NXT-41x launch.
Analysis · ELUT · Life Sciences
A Nasdaq delisting notice landed on August 6, 2026, after the stock traded below $1.00 for 30 consecutive business days, giving the company until February 2, 2027, to regain compliance. To shore up liquidity, a $15 million senior secured term loan was secured from Avenue Capital Group, with $10 million funded immediately and $5 million available as a delayed draw. The loan includes warrants exercisable for 1,395,348 shares at $0.86 per share, adding potential dilution. Additionally, an agreement to sell the SimpliDerm business for up to $11 million will streamline operations but also removes a significant revenue source. The company reported a Q2 net loss of $7.6 million and cash of $19.9 million, indicating ongoing financial challenges.
At the time of this filing, ELUT was trading at $0.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.6M. The 52-week trading range was $0.50 to $2.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.